fda decision on compounded tirzepatide 📢Important Update Tirzepatide! Due to recent FDA regulations, the compounding Compounded Semaglutide & Tirzepatide 2025:

The comparison of these two forms of semaglutide is critical in understanding the potential trade-offs between convenience and therapeutic effectiveness

Generally, brand-name Mounjaro from a Mexican pharmacy at $89 to $160 per vial is comparable to or cheaper than US compounded tirzepatide at $150 to $500 per month

In the base case, BMI-associated utility was estimated based on a linear model with a fixed utility decrement per unit BMI increase, accounting for age, prior history of heart disease, hypertension, and smoking status using patient-reported outcome scores from the SCALE trial for liraglutide 3 mg, which were mapped to utility scores

Most reconstitution guides focus on this size because it is what the majority of researchers are working with

And maybe Pfizer missed an opportunity to set foot in the GLP-1 market because of a decision it made back in the 90s